All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status

Abstract

All-trans retinoic acid (ATRA) and pre-upfront arsenic trioxide (ATO) have revolutionized the therapy of acute promyelocytic leukemia (APL). However, internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations is associated with increased risk of relapse. The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA, idarubicin (IDA) and/or ATO, followed by ATRA plus ATO along with anthracycline, as consolidation therapy. A total of 72 patients newly diagnosed with APL were included in this study. 83.3% of the patients achieved complete remission (CR) after induction therapy. FLT3-ITD mutations were detected in 16 (22.2%) patients and closely related to bcr-3 PML-RARa transcript (P<0.001). The 5-year overall survival (OS) rate was 100% in both FLT3-ITD^positive and FLT3-ITD^negative groups, and there was no significant difference in 5-year event-free survival (EFS) between the two groups (78.3% vs. 83.3%, P=0.85). ATRA plus ATO and anthracycline-based chemotherapy achieved great outcome in newly diagnosed APL regardless of the FLT3-ITD mutation status.

Keywords

all-trans retinoic acid / acute promyelocytic leukemia / arsenic trioxide / anthracycline / internal tandem duplication of FMS-like tyrosine kinase 3

References

[1] GrignaniF, FerrucciPF, TestaU, et al.. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell, 1993, 74(3): 423-431

[2] IlandH, BradstockK, SeymourJ, et al.. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica, 2012, 97(2): 227-234

[3] KayserS, RahméR, Martínez-CuadrónD, et al.. Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia, 2020, 34(9): 2333-2341

[4] BrecciaM, LoglisciG, LoglisciMG, et al.. FLT3-ITD confers poor prognosis in patients with acute promyelocytic leukemia treated with AIDA protocols: long-term follow-up analysis. Haematology, 2013, 98(12): e161-e163

[5] Sanz J, Labopin M, Sanz MA, et al. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplant, 2020. doi: https://doi.org/10.1038/s41409-020-01162-0

[6] LamS S, LeungAYH. Overcoming resistance to FLT3 inhibitors in the treatment of FLT3-Mutated AML. Int J Mol Sci, 2020, 21(4): 1537

[7] FanY, CaoY, BaiX, et al.. The clinical significance of FLT3 ITD mutation on the prognosis of adult acute promyelocytic leukemia. Hematology, 2018, 23(7): 379-384

[8] GaleRE, HillsR, PizzeyAR, et al.. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood, 2005, 106(12): 3768-3776

[9] SanzMA, MartínG, Díaz-MediavillaJ. All-transretinoic acid in acute promyelocytic leukemia. N Engl J Med, 1998, 338(6): 393-394

[10] Lucena-AraujoAR, KimHT, JacomoRH, et al.. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol, 2014, 93(12): 2001-2010

[11] SanzMA, FenauxP, TallmanMS, et al.. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood, 2019, 133(15): 1630-1643

[12] ChoudhryA, DelougheryTG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol, 2012, 87(6): 596-603

[13] WattsJM, TallmanMS. Acute promyelocytic leukemia: what is the new standard of care?. Blood Rev, 2014, 28(5): 205-212

[14] BabaSM, ShahZA, PandithAA, et al.. Influence of bcr-3 PML-RARα transcript on outcome in acute promyelocytic leukemia patients of Kashmir treated with all-trans retinoic acid and/or arsenic tri-oxide. Cancer Genet, 2019, 231–232: 14-21

[15] PoiréX, MoserBK, GallagherRE, et al.. Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leuk Lymphoma, 2014, 55(7): 1523-1532

[16] Cumbo C, Orsini P, Anelli L, et al. FLT3Nanopore sequencing sheds a light on the gene mutations complexity in acute promyelocytic leukemia. Leuk Lymphoma, 2020:1–10

[17] NathS, BhattacharyyaJ, ChandraP, et al.. Clinicopathological significance of common genetic alterations in patients with acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther, 2020, S1658–3876(20): 30 121-30 127

[18] CicconiL, DivonaM, CiardiC, et al.. PML-RARa kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy. Leukemia, 2016, 30(10): 1987-1992

[19] KumsaenP, FucharoenG, SirijerachaiC, et al.. FLT3-ITD Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand. Asian Pac J Cancer Prev, 2016, 17(9): 4395-4399

[20] RasekhE, ElsayedG, MadneyY, et al.. Prognostic Significance of bcr-1 and bcr-3 Isoforms of PML-RARA and FLT3-ITD in Patients with Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk, 2020, 20(3): 156-167

[21] NieL, MaR, YuanX, et al.. The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia. Leuk Lymphoma, 2020, 61(10): 2482-2487

[22] PicharskiGL, AndradeDP, FabroALMR, et al.. The impact of Flt3 gene mutations in acute promyelocytic leukemia: A meta-analysis. Cancers (Basel), 2019, 11(9): 1311

[23] BrecciaM, CicconiL, Lo-Cocof. ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?. Curr Opin Hematol, 2014, 21(2): 95-101

[24] de la SernaJ, MontesinosP, VellengaE, et al.. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008, 111(7): 3395-3402

[25] KuchenbauerF, SchochC, KernW, et al.. Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol, 2005, 130(2): 196-202

[26] NogueraNI, BrecciaM, DivonaM, et al.. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia, 2002, 16(11): 2185-2189

[27] ShihLY, KuoMC, LiangDC, et al.. Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer, 2003, 98(6): 1206-1216

[28] EsnaultC, RahméR, RiceKL, et al.. FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias. Blood, 2019, 133(13): 1495-1506

[29] WangLN, TangYL, ZhangYC, et al.. Arsenic trioxide and all-trans-retinoic acid selectively exert synergistic cytotoxicity against FLT3-ITD AML cells via co-inhibition of FLT3 signaling pathways. Leuk Lymphoma, 2017, 58(10): 2426-2438

[30] RegoEM, PandolfiPP. Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models. Semin Hematol, 2001, 38(1): 54-70

[31] SanzMA, MontesinosP, RayónC, et al.. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010, 115(25): 5137-5146

[32] RaffouxE, RousselotP, PouponJ, et al.. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncolo, J Clin Oncol, 2003, 21(12): 2326-2334

[33] LiuCC, WangH, WangWD, et al.. Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia. Onco Targets Ther, 2015, 8: 3297-3303

[34] ThomasX, HeibligM. Acute promyelocytic leukemia. Cancers, 2020, 12(12): 3718

[35] GhavamzadehA, JaliliM, RostamiS, et al.. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA. Leuk Res, 2018, 66: 85-88